Licensed vaccine
Flucelvax Quadrivalent
FDA-licensed vaccine · Seqirus, Inc. · STN: BL 125408
Key facts
| Trade name | Flucelvax Quadrivalent |
|---|---|
| Proper name | Influenza Vaccine |
| Manufacturer | Seqirus, Inc. |
| Submission tracking number (STN) | : BL 125408 |
| FDA product areas | Biologics |
| Recent FDA documents | June 30, 2023 Approval Letter - Flucelvax Quadrivalent, February 28, 2023 Approval Letter - Flucelvax, July 1, 2022 Approval Letter - Flucelvax Quadrivalent, Clinical Review (125408/351) - Flucelvax Quadrivalent, Statistical Review (125408/351) - Flucelvax Quadrivalent, October 14, 2021 Approval Letter - Flucelvax Quadrivalent, July 2, 2021 Approval Letter - Flucelvax, Statistical Review (STN: 125408/329) - Flucelvax Quadrivalent, Clinical Review (STN: 125408/329) - Flucelvax Quadrivalent, March 3, 2021 Approval Letter - Flucelvax Quadrivalent, July 2, 2020 Approval Letter - Flucelvax, September 18, 2019 Approval Letter - Flucelvax |
| FDA page updated | Jul 6, 2023 |
| FDA product page | fda.gov |
At a glance
- 10–99 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: